Background: We conducted a phase I trial to determine the safety and maximum tolerated dose 
Introduction
Docetaxel is the most active drug in metastatic breast cancer. Phase II and III clinical trials show that docetaxel alone, or in combination with other cytotoxic drugs, produces superior response rates, time to progression and, in some cases, provides a survival advantage over non-docetaxel containing regimens [1] [2] [3] [4] . Doxorubicin is also one of most active drugs in breast cancer; however, its use is limited by cumulative cardiac toxicity [5 -7] . Non-pegylated liposome-encapsulated doxorubicin (Myocete; D-99) has similar anti-tumor activity to unencapsulated free doxorubicin, but causes less myocardial damage when administered as a single-agent or in combination with cyclophosphamide in metastatic breast cancer [8 -11] . Based on the improved therapeutic index of D-99 relative to doxorubicin with respect to cumulative cardiac toxicity, we conducted a phase I study to determine the safety and to define the maximum tolerated dose (MTD) of D-99 and weekly docetaxel.
Patients and methods

Patient eligibility
Patients age 18 years or older with histologically confirmed breast cancer, evidence of metastatic disease, and no prior chemotherapy for metastases were eligible. Patients who had received prior adjuvant taxanes and/or doxorubicin were eligible if the chemotherapy was completed more than 6 months prior to study entry, and the total cumulative dose of adjuvant doxorubicin was limited to < _ 300 mg/M 2 . Hormone therapy in the adjuvant or metastatic setting was permitted provided it was discontinued at least 3 weeks before study entry.
Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status < _ 2, and the following organ function: platelets > _ 100 000 cells/mm 3 ; absolute neutrophil count > _ 1500 cells/mm 3 ; hemoglobin > _ 10 g/dl; serum creatinine <2.0 mg/dl; and pretreatment left ventricular ejection fraction (LVEF) > _ 50%. Due to the increased risk of side-effects of docetaxel with impaired liver function, the total bilirubin was required to be less than or equal to the upper limit of normal (ULN); AST and ALT < _ 2.5 times ULN if alkaline phosphatase was normal; or alkaline phosphatase < _ 4 times ULN if AST and ALT were normal. Patients were excluded for a known hypersensitivity to taxanes, anthracyclines, polysorbate 80, eggs or eggs products; prior radiotherapy to mediastinal area or internal mammary lymph node exceeding 3500 cGy, or if they received radiation therapy to more than 25% of the bone marrow. Patients with untreated brain metastases were excluded. However, patients *Correspondence to: Dr C. L. Shapiro, B 405 Starling-Loving, 320 West 10th Avenue, Columbus, OH 43210, USA. Tel: +1-614-293-7530; Fax: +1-614-293-7529; E-mail: shapiro-1@medctr.osu.edu with previously treated brain metastases were eligible if they were stable for at least 3 months after surgery and/or radiation and were off steroids. Patients were not required to have bi-dimensionally measurable disease; if measurable disease was present, it was evaluated using standard response criteria (see below). The Institutional Review Board of the Ohio State University approved the study protocol, and written informed consent was obtained from each patient.
Treatment plan
D-99 was provided by Elan Pharmaceuticals, Inc. (Princeton, NJ) in a three-vial set containing liposomes for injection 2 ml (100 mg/ml), doxorubicin hydrochloride powder (50 mg/vial) and buffer for injection 3 ml (sodium carbonate 17.6 mg/ml). The drug was prepared in the pharmacy according to standard manufacturers instructions just before administration. Docetaxel was obtained from commercial sources. 
Definition of dose limiting toxicity (DLT) and criteria for dose escalation and reductions
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, version 2.0. A dose limiting toxicity (DLT) occurring in cycle 1 was defined as follows: any grade 4 neutropenia lasting more than 7 days; febrile neutropenia; or any grade 4 non-hematologic toxicity, grade 3 mucositis or stomatitis lasting more than 3 days; or any other grade 3 non-hematologic toxicity that did not revert to grade 1 or less within 35 days. Cohorts of three to six patients were treated at a given dose level. There was no intra-patient dose escalation. Escalation to the next higher dose level took place only after all three patients had completed the first treatment cycle without evidence of DLT. If there was one DLT among the initial three patients, an additional three patients were treated at the same dose level. If two or less patients out of six experienced DLT, the dose was escalated to the next level. If more than two patients out of three experienced DLT in cycle 1, the dose was not escalated to the next level, and the MTD was defined as the next lower dose level.
Patients were treated until disease progression, unacceptable toxicity, or a maximum of six cycles. There were no dose reductions for D-99. A docetaxel dose reduction of 5 mg/m 2 was permitted for grade 4 neutropenic fever, grade 4 anemia or thrombocytopenia, serum bilirubin level 1.2 Â ULN, or grade 3 or 4 mucositis. Only one docetaxel dose reduction per patient was permitted. Dose delays of up to 14 days were permitted for grade 3 or 4 non-hematologic toxicity that did not revert to < _ grade 1, or for an absolute neutrophil count (ANC) of < _ 1000/mm 3 and or platelet count of < _ 100 000/mm 3 on day 1 of a treatment cycle. Patients who did not revert to < _ grade 1 non-hematologic toxicity or failed to recover ANC >1000/mm 3 or platelet count >100 000/mm 3 after 14 days were removed from the study.
Tumor evaluation and criteria for response
All patients had imaging studies and/or physical examination measurements for assessment of tumor sites within 14 days before starting treatment. The same imaging modalities were used for response evaluation after every two cycles, as well as at the time of discontinuation of study therapy. In those patients with measurable disease the definitions of response were as follows: complete response (CR) was the disappearance of all evidence of disease lasting at least 4 weeks; partial response (PR) was a > _ 50% decrease in the sum of the products of the two longest perpendicular diameters of all measured lesions lasting at least 4 weeks and no new lesions; stable disease (SD) was a < _ 50% decrease or < _ 25% increase in measurable disease and no new lesions; and progressive disease (PD) was a > _ 25% increase in the product of the two longest perpendicular diameters of any measurable disease lesion, or the appearance of a new lesion.
Monitoring for cardiac toxicity
All patients had an electrocardiogram (ECG) within 1 week of study entry, and a multiple-gated radionuclide angiography acquisition (MUGA) scan to quantitate LVEF within 4 weeks before treatment. Subsequent MUGA scans were required after patients received a total cumulative anthracycline dose ( 
Statistical methods
Median time to progression and median overall survival were estimated by the Kaplan-Meier method [12] . Confidence intervals for median time to progression and overall survival were calculated using the Brookmeyer-Crowley method [13] . Exact binomial confidence intervals are reported for all proportions.
Results
Patients characteristics
From September 1999 to April 2002, 21 patients were enrolled. Patient characteristics are described in Table 1 . The median age was 54 years; 20 (95%) patients had an ECOG performance status of 0 or 1; 13 (62%) were postmenopausal; 14 (67%) were hormone receptor positive; and five (25%) were HER2/neu 3+ by immunohistochemistry. Fifteen (71%) patients received prior adjuvant chemotherapy with 12 (57%) receiving prior doxorubicin with a median dose of 240 mg/m 2 (range 120-240 mg/m 2 ). The median baseline LVEF was 64% (range 50% -74%). The skeleton was the most common site of metastases in 12 (57%) patients, followed by liver in eight (38%), and lung in seven (33%). Fourteen (67%) patients had two or more sites of metastases. Sixteen (76%) patients had bi-dimensionally measurable disease.
Results of dose escalation
The median number of treatment cycles was 4 (range 1-6). 
Overall toxicity
Of the 103 treatment cycles, in 20 (19%) the docetaxel doses were reduced, and in 20 (19%) doses were delayed. Table 3 describes hematologic toxicity. Grade 4 neutropenia occurred in 42 (41%) treatment cycles, with 10 (10%) hospitalizations for febrile neutropenia. After a documented episode of febrile neutropenia, G-CSF was started in the majority of patients. Only two (10%) patients required packed red blood cell (PRBC) transfusions for grade 3 anemia, and three (14%) patients received erythropoietin. Non-hematologic toxicity is described in Table 4 . Twenty (19%) treatment cycles were associated with either grade 3 or 4 gastrointestinal toxicities (nausea, vomiting, diarrhea and stomatitis). Severe (grade 3) asthenia was reported in only two (2%) treatment cycles, and there were no instances of palmar plantar erythrodysesthesia. Twenty (19%) treatment cycles were delayed mainly for grade 4 neutropenia and grades 3 or 4 mucositis. Other docetaxelspecific toxicities including asthenia, fluid retention, nail disorders, and eye tearing were virtually all grades 2 or less and did not result in treatment delays or cause patients to be removed from study.
Cardiac toxicity
The median total cumulative anthracycline dose (adjuvant doxorubicin + D-99) was 335 mg/m 2 (range 240-540 mg/m 2 ). Table 5 describes the total cumulative anthracycline dose and incidence of cardiac events. Six (29%) patients received a total cumulative anthracycline dose of 540 mg/m 2 , 14 (66%) received doses ranging from 250 to 480 mg/m 2 , one (5%) received 240 mg/m 2 . All 21 (100%) patients had pre-and 19 (90%) had post-therapy MUGA (Figure 1 ). The median LVEF before treatment was 64%, (range 50% -79%) and 1 month after treatment was 65% (range 51% -79%). For the 12 patients who had received doxorubicin in the adjuvant setting the median baseline LVEF was 64% (range 51% -74%), and 1 month after treatment, the median LVEF was 62% (range 29% -74%).
Three (14%; 95% CI 3% to 36%) patients had cardiac events that occurred either during or within 8 weeks of completing treatment. After a cumulative anthracycline dose of 240 mg/m 2 , patient 1 developed a 27% decrease in LVEF from a pre-study baseline of 79% to 52% after four cycles of D-99. She was asymptomatic but was removed from study per protocol guidelines.
Two (10%; 95% CI 1% to 30%) patients developed grade 3 CHF shortly after completion of study treatment. Both patients received adjuvant doxorubicin dose of 240 mg/m 2 , and total cumulative anthracycline dose (adjuvant doxorubicin + D-99) of 540 mg/m 2 . Patient 2 presented with acute CHF about 7 weeks after completing all six treatment cycles at the dose level of 50/30. Her pre-and post-treatment LVEF were 59% and 51%, respectively, but at the time she presented with symptomatic CHF, the LVEF was 29%. This patient responded to medical treatment for CHF and subsequent LVEF improved to 62%.
Patient 3 developed CHF about 6 weeks after completing six cycles of study treatment at the dose level of 50/25. She also had a history of left-sided postmastectomy chest wall irradiation after her adjuvant chemotherapy. Her pre-and post-study LVEF were 57% and 52%, respectively, but at the time of symptoms of CHF, the LVEF was 30%. In addition, there was evidence of thrombus in the left ventricle and small pericardial effusion. Patient 3 was treated with anticoagulation and was discharged from the hospital on medication for CHF. Ten days after discharge she presented to an emergency room with acute respiratory failure and died. There was no post-mortem examination. Patients 2 and 3 did not receive chemotherapy, hormonal treatment, or any other potential cardiotoxic drug after completing study treatment and before presenting with CHF. In addition, both patients had no evidence of acute myocardial injury by serial enzymes or electrocardiographic changes, or pulmonary embolus at the time of presentation of CHF.
Two additional patients developed cardiac events 4 and 9 months after completion of study therapy, but only after starting another phase I clinical trial of trastuzumab (Herceptinw) and interleukin 12 (IL-12).
Response and survival data
Eight (38%) patients were removed from the study: four (19%) for PD, including one who expired from respiratory failure due to refractory progressive malignant effusions, and four (19%) for DLT. Sixteen patients had bidimensional measurable disease and were evaluable for response ( Table 6 ). The overall response rate for all 21 patients was 29% (95% CI 11% to 52%), and 38% (95% CI 15% to 65%) among the patients with measurable disease. The time to progression (TTP) and overall survival in all patients was 8.8 months (95% CI 3.7 -12.4 months) and 22.2 months (95% CI 15.4 -29.7 months), respectively. 
Discussion
Dose escalation of docetaxel in combination with D-99 was limited by grade 3 and 4 mucositis and febrile neutropenia. Grade 4 neutropenia was the most frequent adverse event occurring in 41% of treatment cycles. In addition, three (14%) patients had a protocol-defined cardiotoxicity, including two (10%) with CHF after they received a total cumulative anthracycline dose of 540 mg/m 2 . Serial measurements of resting LVEF by radionuclide ventriculography in the patients who developed CHF failed to predict development of doxorubicin cardiomyopathy. This is consistent with other studies that show the sensitivity of resting LVEF to predict subsequent CHF is only about 50% [14] . This study did not use exercise radionuclide ventriculography, which may increase the sensitivity of detecting subclinical myocardial damage when the resting LVEF is in the normal range [6] . Previous studies of D-99 as a single agent or in combination with cyclophosphamide showed 0%-2% incidence of CHF. ) and docetaxel (75-85 mg/m 2 ) given every 3 weeks, there were no cases of CHF or decline in LVEF sufficient to remove the patients from the study [15] . The incidence of CHF ranges from 0% to 10% in clinical trials of conventional doxorubicin combined with docetaxel (Table 7 ) [16 -20] . In contrast, no CHF was observed using pegylated liposomal doxorubicin (Doxil w ) in combination with docetaxel [21] [22] [23] [24] . There are several possible explanations for the relatively high incidence of CHF observed in this study. First, because of the small trial population, the true proportion of CHF is as low as 1% or as high as 30%. It is also possible that patient 3 developed CHF because she had . In a prospective randomized adjuvant trial, patients with localized breast cancer received 225 or 450 mg/m 2 adjuvant doxorubicin, and a portion of them received postmastectomy radiation [25] . Acute and long-term cardiac events, including CHF and myocardial infarction, were the primary end points of the study. Whereas no increase cardiac events occurred in patients receiving 225 mg/m 2 of doxorubicin along with any dose-volume of chest wall radiation, patients who received 450 mg/m 2 and moderate or high dose-volumes of chest wall radiation were at significantly higher risks of acute and long-term cardiac events [25] .
Another possibility is that weekly administration of docetaxel had a significant effect on pharmacokinetic (PK) and toxicity profile of D-99. Unlike paclitaxel, there is little or no evidence that docetaxel affects the PK of doxorubicin or pegylated liposomal doxorubicin [26, 27] . To our knowledge, however, there are no PK studies of docetaxel and D-99 reported. Our intention was to collect PK samples of D-99 on a subset of patients to evaluate peak plasma levels and clearance of drug. Unfortunately, blood samples were collected from only one patient after the study sponsor withdrew support for PK analysis due to methodological problems with D-99 assay.
The primary objective of this phase I trial was not to define the response rate for this combination. However, the overall response rate of 29%, and 38% for patients who had measurable disease, was below the response rates observed by other investigators using combinations of conventional or liposomal doxorubicin with docetaxel in similar MBC patients (Table 7) . Likewise, the low response rate in this trial is consistent with the 33% response rate in the only other phase I trial of D-99 and docetaxel [15] .
D-99 combined with weekly docetaxel as administered in this phase I trial did not show improved cardiac safety and had low antitumor activity in MBC patients without prior chemotherapy for metastases. Phase II testing of this combination is not recommended. Additional trials, using different doses and schedules, are required to evaluate the potential cardiac, as well as other, side-effects and efficacy of D-99 and docetaxel.
